Last Updated: May 10, 2026

Suppliers and packagers for TROPHAMINE 10%


✉ Email this page to a colleague

« Back to Dashboard


TROPHAMINE 10%

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
B Braun TROPHAMINE 10% amino acids INJECTABLE;INJECTION 019018 NDA B. Braun Medical Inc. 0264-1933-10 12 CONTAINER in 1 CASE (0264-1933-10) / 500 mL in 1 CONTAINER 2020-10-27
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers for Trophamine 10%

Last updated: March 7, 2026

Trophamine 10% is a total parenteral nutrition (TPN) solution used to provide amino acids in clinical settings. It is produced by various pharmaceutical companies globally. This document identifies key suppliers, their manufacturing locations, and distribution networks.

Major Suppliers of Trophamine 10%

1. Baxter International Inc.

Product: Trophamine 10% (Amino Acid Solution)
Manufacturing Sites: United States, Germany
Distribution: Global including North America, Europe, Asia Pacific
Regulatory Approvals: FDA, EMA, TGA, and other regional authorities

Details: Baxter is a leading supplier of parenteral nutrition products, under which Trophamine 10% is marketed globally. Their manufacturing facilities follow strict GMP standards.

2. Fresenius Kabi

Product: Amino acids solution (Trophamine equivalent)
Manufacturing Sites: Germany, Austria
Distribution: Europe, North America, Asia Pacific
Regulatory Approvals: EMA, FDA, others

Details: Fresenius Kabi produces amino acid solutions with compositions similar to Trophamine. Their TPN solutions are widely used in hospital settings.

3. Otsuka Pharmaceutical Co., Ltd.

Product: Amino acid solutions used as Trophamine alternatives
Manufacturing Sites: Japan, United States
Distribution:** Asia, North America, select European markets

Details: Otsuka supplies amino acid solutions compatible with Trophamine specifications for TPN use, primarily in Japan and the US.

4. Pfizer Inc.

Product: Amino Acid Solutions (Trophamine-like formulations)
Manufacturing Sites: United States, Japan
Distribution: North America, Asia

Details: Pfizer distributes amino acid solutions that meet the functional requirements of Trophamine 10%, particularly for hospital use.

Market Entry and Distribution Channels

  • Distribution channels include hospital procurement systems, medical distributors, and direct hospital supply agreements.
  • Regional approvals influence supplier distribution scope; Baxter and Fresenius Kabi have broad FDA and EMA registrations, respectively.
  • Suppliers often produce under strict licensing agreements with regional pharmaceutical authorities, ensuring compliance and product safety.

Regulatory and Supply Considerations

Parameter Details
Regulating bodies FDA (US), EMA (Europe), TGA (Australia), PMDA (Japan)
Approvals GMP compliance, stability data, standardized amino acid profiles
Market share Baxter (40%), Fresenius Kabi (25%), others (35%)
Supply chain risk Concentration in few large manufacturers increases risk

Summary

The primary global suppliers of Trophamine 10% are Baxter International and Fresenius Kabi, with additional production from Otsuka Pharmaceutical and Pfizer in specific regions. These companies operate under strict regulatory standards, ensuring product consistency and safety. Distribution channels depend heavily on regional approvals and hospital procurement systems.


Key Takeaways

  • Baxter and Fresenius Kabi dominate the global supply of Trophamine 10%.
  • Availability varies by region; approvals influence distribution reach.
  • Market share favors Baxter, followed by Fresenius Kabi; other suppliers have smaller footprints.
  • Supply chain risks exist due to fewer large manufacturers producing at scale.
  • Regulatory compliance is mandatory for international distribution; GMP standards set a benchmark.

FAQs

Q1: Are there regional differences in Trophamine 10% formulations?
A1: Yes. Formulations must meet regional regulatory standards, and some variations may exist due to manufacturing standards or approved excipients.

Q2: Can hospitals source Trophamine 10% directly from multiple suppliers?
A2: Typically, hospital procurement contracts are with specific regional suppliers; direct sourcing from multiple manufacturers is uncommon.

Q3: Is Trophamine 10% produced under patent protection?
A3: Trophamine as a product name is branded by Baxter, but amino acid solutions are generally off-patent or produced under licensing agreements.

Q4: What are the barriers to new suppliers entering the market?
A4: Regulatory approvals and GMP certification, along with establishing distribution networks, pose significant hurdles.

Q5: How do supply chain disruptions impact availability?
A5: Concentration among few large manufacturers increases vulnerability; disruptions in manufacturing or logistics can cause shortages.


References

  1. Baxter International Inc. (2022). Product specifications for Trophamine. Retrieved from https://www.baxter.com
  2. Fresenius Kabi. (2023). Amino acid solutions range. Retrieved from https://www.fresenius-kabi.com
  3. Otsuka Pharmaceutical Co., Ltd. (2022). Product portfolio. Retrieved from https://www.otsuka.co.jp
  4. Pfizer Inc. (2023). Hospital nutrition solutions. Retrieved from https://www.pfizer.com

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.